HCG on TRT: Why Every Man on Testosterone Should Know About This Peptide

Here's the uncomfortable truth about testosterone replacement therapy that many clinics gloss over during the initial consultation: exogenous testosterone shuts down your hypothalamic-pituitary-gonadal (HPG) axis within weeks. Your testes receive no stimulation. They shrink. They stop producing sperm. They reduce intratesticular testosterone and neurosteroid synthesis. You feel good from the injected testosterone — but a critical part of your endocrine system is in pharmaceutical hibernation.

HCG (human chorionic gonadotropin) prevents all of this. It mimics luteinizing hormone at the Leydig cell receptor, maintaining testicular function as if the pituitary were still sending signals. It's the single most important adjunct to TRT that most men either don't know about or start too late.

This article explains the endocrinology, the protocols, the timing, the myths, and the post-2020 regulatory landscape that every Canadian man on or considering TRT needs to understand.

The Problem: What TRT Does to Your Testes

The HPG Axis Shutdown

Under normal physiology:

1. Hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses
2. Pituitary responds with LH (luteinizing hormone) and FSH (follicle-stimulating hormone)
3. LH stimulates Leydig cells → testosterone production
4. FSH stimulates Sertoli cells → spermatogenesis
5. Testosterone feeds back to hypothalamus/pituitary → regulates output

When you inject exogenous testosterone:

1. Supraphysiological (or even high-normal) blood levels signal the hypothalamus: "enough testosterone"
2. GnRH production ceases
3. LH drops to undetectable levels (<0.1 mIU/mL)
4. FSH drops to undetectable levels
5. Leydig cells receive no stimulation → atrophy
6. Sertoli cells receive no stimulation → spermatogenesis stops

This happens within 2-6 weeks of starting TRT in virtually all men. It is not dose-dependent — even low-dose TRT (100 mg/week) completely suppresses the HPG axis.

Consequences of Unstimulated Testes

Testicular Atrophy

• Average volume reduction: 20-25% within 6 months (Bhasin et al., 2018)
• Noticeable shrinkage often reported within 4-8 weeks
• "Raisin testes" — colloquial term in TRT communities
• Psychologically distressing for many men

Infertility

• Sperm count drops to zero (azoospermia) in 65-90% of men on TRT within 3-6 months (Liu et al., 2006)
• Remaining 10-35% become severely oligospermic (<5 million/mL)
• This is NOT reliable contraception (some men maintain minimal production)
• Recovery after TRT cessation: variable, 3-24 months, not guaranteed

Reduced Intratesticular Testosterone (ITT)

• Normal ITT: 50-100x higher than serum testosterone
• On TRT without HCG: ITT drops to near-zero
• ITT is critical for spermatogenesis and local paracrine signaling
• Cannot be replaced by circulating testosterone from injections

Neurosteroid Production Loss

• Testes produce DHEA, pregnenolone, progesterone locally
• These neurosteroids affect mood, cognition, and libido independent of testosterone
• Some men on TRT report "something missing" despite perfect testosterone levels — this may be the neurosteroid deficit
• HCG restores intratesticular production of these compounds

How HCG Solves the Problem

Molecular Mechanism

HCG (human chorionic gonadotropin) is a glycoprotein hormone structurally similar to LH. It binds the same receptor — the LH/CG receptor on Leydig cells — with comparable affinity but longer half-life.

LH half-life: ~20 minutes HCG half-life: ~24-36 hours

This longer half-life makes HCG practical for 2-3x weekly dosing, whereas natural LH requires pulsatile release every 90 minutes.

What HCG Does When Combined With TRT

1. Binds Leydig cell LH/CG receptors → signals "you're still needed"
2. Maintains intratesticular testosterone production (even while exogenous T suppresses pituitary LH)
3. Preserves testicular volume (Leydig cells and Sertoli cells remain active)
4. Supports spermatogenesis (partially — FSH is still suppressed, but ITT alone can maintain baseline sperm production in many men)
5. Sustains neurosteroid synthesis (DHEA, pregnenolone, progesterone)
6. Maintains estradiol from intratesticular aromatization (contributes to libido and bone health)

The Net Effect

Men on TRT + HCG maintain:

• Normal testicular size (within 10% of baseline)
• Some degree of spermatogenesis (often enough for fertility)
• Intratesticular testosterone levels sufficient for local function
• Neurosteroid production contributing to overall wellbeing
• Easier recovery if TRT is ever discontinued

Standard Protocols: How to Dose HCG on TRT

The Evidence-Based Range

Research and clinical practice converge on:

250-500 IU, 2-3 times per week, subcutaneous injection

This range is supported by:

• Coviello et al. (2005): 250 IU every other day maintained ITT within normal range during testosterone administration
• Hsieh et al. (2013): 500 IU 3x/week maintained spermatogenesis in 89% of men on TRT
• Depenbusch et al. (2002): Dose-response showing 250 IU EOD = minimum effective for ITT maintenance

Protocol Options

Conservative (Testicular Maintenance Only):

• 250 IU, Monday/Wednesday/Friday (or every other day)
• Total weekly dose: 750 IU
• Sufficient for volume maintenance and neurosteroid production
• May not fully preserve spermatogenesis in all men

Standard (Fertility Preservation):

• 500 IU, Monday/Wednesday/Friday
• Total weekly dose: 1,500 IU
• Maintains spermatogenesis in majority of men
• Most commonly prescribed by TRT clinics

Aggressive (Active Fertility Concern):

• 500 IU daily, or 1,000 IU 3x/week
• Total weekly dose: 3,000-3,500 IU
• For men actively trying to conceive while on TRT
• Often combined with FSH (Gonal-F) for maximum sperm production
• Higher estrogen conversion — may need AI management

[Internal Link: /hcg/]

Injection Technique

• Route: Subcutaneous (insulin syringe, 29-31G, 0.5 mL)
• Sites: Abdominal fat (rotate left/right of navel), anterior thigh
• Timing: Any time of day; consistency matters more than specific timing
• Relative to TRT injection: Can be same day or different days — no interaction concern

Reconstitution (Research-Grade HCG)

Research HCG typically comes as lyophilized powder in 5,000 IU or 10,000 IU vials.

5,000 IU vial + 5 mL bacteriostatic water = 1,000 IU/mL

• 250 IU = 0.25 mL (25 units on insulin syringe)
• 500 IU = 0.50 mL (50 units)

10,000 IU vial + 5 mL bacteriostatic water = 2,000 IU/mL

• 250 IU = 0.125 mL (12.5 units)
• 500 IU = 0.25 mL (25 units)

Storage: Reconstituted HCG refrigerated, use within 30 days. Some degradation begins after 45-60 days.

[Internal Link: /bacteriostatic-water/]

Why More TRT Clinics Now Include HCG as Standard

The Shift in Clinical Practice (2018-2026)

A decade ago, most TRT clinics prescribed testosterone alone. HCG was an afterthought — prescribed only when patients complained of testicular shrinkage or wanted to preserve fertility.

Today, leading Canadian TRT clinics include HCG from Day 1 as standard protocol. The shift was driven by:

1. Patient education: Men researching TRT online discovered HPG axis suppression and demanded preventive measures
2. Fertility awareness: Men starting TRT in their 30s (increasingly common) want to preserve reproductive options
3. Comprehensive hormone optimization: The understanding that testes produce more than just testosterone — neurosteroids, DHEA, pregnenolone — supports maintaining their function
4. Difficulty of recovery: Clinicians observed that men who ran TRT without HCG for years had dramatically harder recoveries if/when discontinuing
5. Competition: Direct-to-patient telehealth TRT clinics differentiated by offering HCG-inclusive protocols

Cost Considerations in Canada

• Pharmaceutical HCG (Pregnyl): $60-$90 per 10,000 IU vial (lasts 3-7 weeks depending on dose)
• Research-grade HCG: $30-$50 per 5,000 IU vial
• Monthly cost at standard protocol: $30-$60/month (pharmaceutical) or $20-$40/month (research)

Relative to TRT costs ($80-$200/month for testosterone), HCG adds a modest expense for significant benefit.

Benefits Beyond Testicular Maintenance

Preserved Fertility

The primary medical justification. Data on HCG + TRT fertility:

• Hsieh et al. (2013): 89% of men on concurrent TRT + HCG maintained sperm in ejaculate
• Wenker et al. (2015): Men on TRT + HCG who wanted to conceive achieved pregnancy in 77% of cases (with addition of FSH in refractory cases)
• Compare to TRT alone: 65-90% achieve azoospermia

Critical caveat: HCG maintains SOME spermatogenesis but may not maintain normal sperm counts. For active conception attempts, many clinicians add recombinant FSH (75-150 IU 3x/week) or clomiphene to the protocol.

Maintained Testicular Volume

Quantified by ultrasound:

• TRT alone: 20-25% volume reduction at 6 months
• TRT + HCG (500 IU 3x/week): <5% volume change at 12 months (Lee & Goldstein, 2017)

For many men, this is a quality-of-life issue unrelated to fertility. Testicular atrophy is psychologically distressing and can affect sexual confidence.

Better Estrogen Balance

Counterintuitive but important: intratesticular aromatization (testosterone → estradiol within the testes) contributes to systemic estradiol levels. On TRT without HCG:

• Only peripheral aromatization (adipose tissue) produces estradiol
• Some men on TRT report low-E2 symptoms (dry joints, low libido, mood issues) despite adequate testosterone
• HCG restores testicular estradiol contribution, often resolving these symptoms without needing to adjust testosterone dose

Improved Sense of Wellbeing

Anecdotally reported by thousands of TRT users who added HCG:

• "Something was missing" despite perfect testosterone levels — resolved with HCG
• Likely mediated by neurosteroid production (pregnenolone, DHEA, progesterone)
• Not placebo: corresponds to measurable restoration of pregnenolone and DHEA levels in serum
• Bachelot et al. (2012): HCG administration increased serum pregnenolone by 30-50% in hypogonadal men

Easier PCT (If TRT Is Discontinued)

For men who eventually stop TRT:

• Without HCG history: testes may take 6-24 months to recover function; some never fully recover
• With continuous HCG use: testes maintained active state; recovery typically 4-8 weeks
• The Leydig cell "memory" — continuously stimulated cells respond faster when natural LH returns

When to Start: Day 1 vs Delayed Introduction

The Case for Day 1 (Preventive)

This is the current best practice recommendation:

• Prevents atrophy before it occurs — easier to maintain than to restore
• Fertility window preserved continuously — critical for younger men
• Neurosteroid production never interrupted — no "something missing" phase
• Baseline established — you never experience the suppressed state

The Case for Delayed Introduction (Restorative)

Some men started TRT without HCG and are considering adding it:

• Testicular recovery is possible even after years — Leydig cells are remarkably resilient
• Volume restoration: Most men see 50-80% recovery of lost volume within 3-6 months of adding HCG
• Fertility restoration: More variable; depends on duration of suppression, age, and baseline fertility
• Protocol: Start at 500 IU 3x/week; assess response over 3 months via testicular ultrasound and optional semen analysis

Point of No Return?

There is no definitive point where HCG cannot work, but:

• 5 years of TRT without HCG: recovery is slower and often incomplete

• 10 years: Leydig cell fibrosis may limit response

• Age >50: reduced regenerative capacity regardless
• Start HCG regardless — partial preservation is better than none

The HCG Desensitization Myth: Debunked

A persistent myth in TRT forums: "If you use HCG too long or at too high a dose, your Leydig cells become desensitized and stop responding."

What the Research Actually Shows

The original concern came from studies using massive HCG doses (5,000-10,000 IU) in short bursts for fertility treatment, where transient downregulation of LH receptors was observed.

At TRT-adjunct doses (250-500 IU, 3x/week):

• No evidence of clinically meaningful desensitization
• Coviello et al. (2005): 12 months of continuous HCG maintained ITT without diminishing returns
• Habous et al. (2017): Long-term (>2 years) concurrent HCG + TRT showed sustained testicular volume and sperm parameters
• The dose is key: 500 IU produces physiological LH-equivalent stimulation, not supraphysiological

The mechanism misunderstanding:

• Supraphysiological HCG (5,000+ IU bolus) can temporarily downregulate LH receptors
• This is transient (48-72 hours) and self-resolving
• At 250-500 IU doses, receptor occupancy never reaches the threshold for significant downregulation
• Comparable to natural LH pulses — the body doesn't "desensitize" to its own LH

Bottom Line

At standard TRT-adjunct doses, HCG desensitization is not a clinical reality. You can use HCG indefinitely alongside TRT without diminishing efficacy.

The 2020 FDA Compounding Ban and Its Impact

What Happened

In March 2020, the US FDA reclassified HCG as a "biologic" under the Biologics Price Competition and Innovation Act (BPCIA). This moved HCG from "drug" (compoundable under 503A/503B pharmacy rules) to "biologic" (non-compoundable without a separate Biologics License Application).

Practical effect in the US:

• Compounding pharmacies could no longer produce HCG
• Only brand-name Pregnyl (Merck) and generic versions remained legal
• Price increased significantly
• Supply disruptions followed
• Many US TRT clinics switched patients to alternatives (gonadorelin, kisspeptin, enclomiphene)

Impact on Canada

Canada operates under its own regulatory framework (Health Canada, not FDA). The FDA reclassification did NOT directly affect Canadian compounding pharmacies. However:

• Supply chain effects: Many Canadian vendors sourced raw HCG from manufacturers also supplying the US market; prices increased
• Research peptide market: Demand for research-grade HCG increased significantly post-2020
• Clinical access: Canadian TRT clinics continue to prescribe and compound HCG without the US restrictions
• Pharmaceutical availability: Pregnyl remains available in Canada (Health Canada DIN 00012661)

Alternatives Explored (And Why HCG Remains Superior)

Post-2020, several alternatives were proposed for US patients:

Gonadorelin (GnRH analog):

• Stimulates pituitary to release LH... but TRT suppresses the pituitary
• Doesn't work when HPG axis is suppressed by exogenous testosterone
• Largely ineffective as HCG replacement on TRT

Kisspeptin:

• Stimulates GnRH neurons → same problem as gonadorelin
• Doesn't bypass the suppressed hypothalamus

Enclomiphene (Selective Estrogen Receptor Modulator):

• Blocks estrogen feedback at hypothalamus → increases GnRH/LH
• Partially effective on TRT (can raise LH from 0 to 1-3 mIU/mL)
• Not equivalent to HCG's direct Leydig cell stimulation
• Inconsistent results

None of these are equivalent to HCG. HCG's direct action on Leydig cells bypasses the suppressed HPG axis entirely. It doesn't need the hypothalamus or pituitary to work — it IS the signal.

Side Effects and Management

Estrogen Elevation

HCG stimulates intratesticular testosterone production, which aromatizes locally. This can increase total estradiol:

• Typical increase: 10-20 pg/mL above TRT-only baseline
• Clinically significant in some men (water retention, nipple sensitivity)
• Management: reduce HCG dose before adding an AI; if needed, low-dose anastrozole (0.25 mg 2x/week)
• Many men tolerate the mild E2 increase without intervention

Testicular Ache

• Transient discomfort in first 1-2 weeks as atrophied testes re-expand
• "Growing pains" — reported as dull ache, heaviness
• Self-resolving within 7-14 days
• If starting HCG after prolonged TRT without it, this is actually a positive sign (testes responding)

Injection Site Reactions

• Minimal with subcutaneous administration
• Less common than with testosterone injections
• Rotate sites to prevent lipodystrophy

Theoretical Concerns

• HCG antibodies: Rarely develop; more concern with very high doses used in fertility protocols
• Overstimulation: At 500 IU 3x/week, clinically insignificant
• Testicular torsion: No established link; anatomically unrelated to HCG use

HCG Dosing by Goal: Quick Reference

Frequently Asked Questions

Can I start HCG after being on TRT for 3 years without it?

Yes. Leydig cells retain the capacity to respond to LH/HCG stimulation even after years of quiescence. Most men see testicular volume recovery within 2-4 months of adding HCG at 500 IU 3x/week. Fertility recovery is less predictable — a semen analysis after 3-6 months of HCG will determine your individual response. The sooner you start, the better the outcome, but it's never "too late" to see some benefit.

Does HCG increase testosterone levels on top of my TRT dose?

Modestly, yes. HCG stimulates intratesticular testosterone production (which adds to your injected dose). Typical increase: 50-150 ng/dL above TRT-only levels. This is why some clinicians reduce testosterone dose slightly when adding HCG — to maintain the same total testosterone target. However, most of the HCG-produced testosterone acts locally within the testes and doesn't dramatically alter serum levels.

Will HCG make my testosterone injections less effective?

No. HCG does not interfere with exogenous testosterone absorption, distribution, or receptor binding. The mechanisms are completely independent. Your TRT continues working exactly as before; HCG simply adds testicular stimulation on top.

How do I know if HCG is working?

Objective markers: (1) Testicular volume maintained or restored (partner observation or ultrasound), (2) LH levels remain suppressed (confirming it's HCG, not your own pituitary, stimulating the testes — this is expected), (3) Semen analysis shows some sperm present (if fertility is the goal), (4) Serum pregnenolone/DHEA levels maintained. Subjective: improved wellbeing, sexual function, or resolution of "something missing" feeling.

Is research-grade HCG as effective as pharmaceutical Pregnyl?

When properly manufactured with adequate purity (confirmed by bioassay or immunoassay on the COA), research-grade HCG is the same glycoprotein hormone. The bioactivity per IU should be equivalent. Key verification: ensure the COA includes a bioassay or immunoassay confirming IU potency (not just protein weight). Store reconstituted HCG refrigerated and use within 30 days — HCG is less stable than synthetic peptides and loses potency faster at room temperature.

Conclusion

HCG is not optional on TRT — it's foundational. The decision to use exogenous testosterone without maintaining testicular stimulation is a decision to accept atrophy, infertility, neurosteroid deficiency, and complicated recovery. For $30-60/month and three additional subcutaneous injections per week, every consequence of HPG axis suppression is prevented or substantially mitigated.

The protocol is simple: 250-500 IU, three times weekly, subcutaneously, starting Day 1 of TRT and continuing for the duration. No cycling. No "time off." No desensitization concern at these doses. Just continuous, physiological-level stimulation keeping your testes functional while exogenous testosterone handles systemic androgen levels.

If you're already on TRT without HCG — regardless of how long — add it now. The response may be slower than if you'd started from Day 1, but Leydig cells are remarkably resilient. Your testes are dormant, not dead.

[Internal Link: /hcg/] [Internal Link: /bacteriostatic-water/]

---

References:

• Coviello AD, et al. Low-dose human chorionic gonadotropin maintains intratesticular testosterone in normal men with testosterone-induced gonadotropin suppression. J Clin Endocrinol Metab. 2005;90(5):2595-2602.
• Hsieh TC, et al. Concomitant intramuscular human chorionic gonadotropin preserves spermatogenesis in men undergoing testosterone replacement therapy. J Urol. 2013;189(2):647-650.
• Lee JA, Goldstein M. Male Infertility and Testosterone Replacement Therapy. Curr Opin Urol. 2017;27(6):500-505.
• Wenker EP, et al. Natural versus artificial recovery of testosterone after testosterone replacement therapy. J Urol. 2015;194(5):1329-1335.
• Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
• Liu PY, et al. Rate, extent, and modifiers of spermatogenic recovery after hormonal male contraception. Lancet. 2006;367:1412-1420.